Anderson Raymond, DIR, reported an open-market or private sale at Monopar Therapeutics involving 694.000000 shares for an estimated $76367.76. Reported holdings after the transaction were 26169.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to pro…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to pro…
0 other filings
0 recent txs